Prolyl hydroxylase inhibitors and methods of use
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein
R is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl, 4-ethoxyphenyl, 2-iso-propoxyphenyl, 3-iso-propoxyphenyl, 4-iso-propoxyphenyl, 2-carbamoylphenyl, 3-carbamoylphenyl, 4-carbamoylphenyl, 2-(aziridine-1-carbonyl)phenyl, 3-(aziridine-1-carbonyl)phenyl, 4-(aziridine-1-carbonyl)phenyl, 2-(azetidine-1-carbonyl)phenyl, 3-(azetidine-1-carbonyl)phenyl, 4-(azetidine-1-carbonyl)phenyl, 2-(pyrrolidine-1-carbonyl)phenyl, 3-(pyrrolidine-1-carbonyl)phenyl, 4-(pyrrolidine-1-carbonyl)phenyl, 2-(piperidine-1-carbonyl)phenyl, 3-(piperidine-1-carbonyl)phenyl, 4-(piperidine-1-carbonyl)phenyl, 2-(acetylamino)phenyl, 3-(acetylamino)phenyl, 4-(acetylamino)phenyl, 2-(ethanecarbonylamino)phenyl, 3-(ethanecarbonylamino)phenyl, 4-(ethanecarbonylamino)phenyl, 2-(cyclopropanecarbonylamino)phenyl, 3-(cyclopropanecarbonylamino)phenyl, or 4-(cyclopropanecarbonylamino)phenyl.
2. The compound according to claim 1 , having the formula:
or a pharmaceutically acceptable salt thereof.
3. A method for treating anemia comprising administering to a human or mammal in need of treatment an effective amount of one or more compounds or the pharmaceutically acceptable salt thereof according to claim 1 .
4. A method for promoting wound healing comprising administering to a human or mammal in need of treatment an effective amount of one or more compounds or the pharmaceutically acceptable salt thereof according to claim 1 .
5. A method for treating a disease affected by the level of VEGF, GAPDH, or erythropoietin, comprising administering to a human or mammal in need of treatment an effective amount of one or more compounds or the pharmaceutically acceptable salt thereof according to claim 1 .